MedTrace Logo

Escitalopram for the Treatment of Depression in Alzheimer's Disease

NCT01841125 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2014-08-13

No results posted yet for this study

Summary

Purpose : to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease

Trial Design : A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial with an open-label, 12-week extension

Conditions

Interventions

DRUG

escitalopram

escitalopram 15mg, QD(once a day), Oral medication, 24weeks

DRUG

Placebo

placebo 15mg, QD(once a day), Oral medication

Sponsors & Collaborators

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Seol-Heui HAN, Professor · Kunkuk Universicy Hospital

  • Dong-Won YANG, Professor · Seoul St. Mary's Hospital

  • Sung-Yoon KIM, Professor · Asan Medical Center

  • Kun-Woo PARK, Professor · Korea University Hospital

  • Do-Hoon KIM, Professor · Hanlym University Hospital

  • So-Young MUN, Professor · AJU University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841125 on ClinicalTrials.gov